Beijing Bioeasy Biotech Completes New Strategic Financing Round, HAOYUE Capital Serves as Exclusive Financial Advisor for Consecutive Rounds

VCBeat has learned that Beijing Baicare Biotechnology Co., Ltd., a domestic player in the microfluidic all-in-one nucleic acid testing industry, recently announced the completion of a strategic financing round nearing RMB 100 million. The round was led by a leading global life sciences and diagnostics company, with Hyjoy Capital continuing to serve as the exclusive financial advisor. This financing will support Baicare’s expansion of large-scale production capabilities and the development of its international marketing system.

Beijing Baicare Biotechnology Co., Ltd. has been deeply engaged in the field of microfluidic chips for over a decade, striving to become a global leader in integrated molecular diagnostics and achieving comprehensive coverage of nucleic acid testing across all scenarios. The company has received continuous support from multiple initiatives, including the National Science and Technology Major Project during the 13th Five-Year Plan period. It has established close collaborations with prestigious institutions such as Academician Zhong Nanshan’s team, the Guangzhou Institute of Respiratory Health, the Chinese Academy of Sciences, the Academy of Military Medical Sciences, and Peking Union Medical College Hospital. Holding 51 independent intellectual property rights, the company operates an 11,000-square-meter R&D and production center in Beijing and Tianjin. It has consecutively won awards such as the “Top 10 in the ZGC International Frontier Technology Innovation Competition” and the “HICOOL Global Entrepreneurship Competition.”

Baicare Biotechnology has currently established four independently developed product lines in the areas of high-throughput testing for outpatient and emergency departments, point-of-care testing (POCT), rapid community testing, and home-based mobile diagnostics. Among these, the “iChip-400 Isothermal Nucleic Acid Amplification Analyzer” and the “Respiratory Pathogen Nucleic Acid Detection Kit” have obtained Class III medical device registration certificates from the National Medical Products Administration (NMPA) and have been highly recognized by numerous top-tier hospitals in China. The “Onestart-1000 Chip-Based Nucleic Acid Amplification Analyzer” meets FDA CLIA waiver requirements and has also obtained NMPA Class III registration approval. The new product, “Superone-8/16 Ultra-Rapid Extraction and Amplification Integrated System,” enables multi-sample testing within half an hour. It sells well both domestically and internationally, covering 33 countries and regions through 52 distributors, and has received strong market acclaim.

With the support of this round of capital, Baicare will accelerate the R&D and registration of new products, strengthen the layout of overseas sales channels, and enhance the visibility and reputation of its products in the international market.

POCT, the acronym for Point-of-Care Test, is known as bedside testing and refers to rapid diagnosis performed at the patient's side. Molecular POCT refers to POCT products in the field of nucleic acid testing, which can achieve“Sample-in, result-out”, which significantly reduces diagnostic time and provides patients with maximum convenience for seeking medical attention within the optimal time window, making it an essential need in specific scenarios.

Globally, molecular POCT holds vast development prospects and is one of the rapidly growing segments within the in vitro diagnostics industry. It can be widely applied in various settings, including hospital clinical laboratories, intensive care units (ICUs), operating rooms, emergency departments, physicians’ offices, clinics, pharmacies, and homes.

Driven by the overarching trend of developing China’s tiered diagnosis and treatment system, the domestic molecular POCT market will continue to experience substantial growth. As medical institutions at all levels assume distinct healthcare functions, the grassroots healthcare market—particularly in lower-tier regions—will emerge as a vast blue ocean for POCT.

Mr. Zhang Guohao, Founder of BaicareHe stated that it was a great honor to gain the recognition of the investors in this round. Baicare Biotechnology is currently in a period of rapid development, and the support from top-tier international partners will elevate the company to new heights. “Global Leader” is our goal; “Higher, Faster, Stronger, Together” is our style; and “Cultivating Outstanding Talents” is our direction for talent development. We will continue to strive to better serve users worldwide.

Mr. Yao Yuan, Vice President of Investment Banking at Haoyue CapitalWe are greatly honored to once again serve as the exclusive financial advisor for Baicare’s current round of financing. As an innovative platform, microfluidic chips enable the development of applications across multiple fields. In the area of pathogen detection, international giant bioMérieux, which also adopts microfluidic chip technology, has already achieved significant market success. With China’s effective control of the COVID-19 pandemic and the introduction of new policies, pathogen testing is expected to expand into diverse scenarios ranging from clinical settings to home use. Currently, various detection methods face challenges such as site limitations, biosafety concerns, high costs, and sensitivity issues. As a pioneer in the research and development of all-in-one nucleic acid testing devices in China, Beijing Baicare Biotechnology Co., Ltd. boasts a robust microfluidic technology platform that fully leverages the advantages of point-of-care testing, closed reagent systems, low cost, and high sensitivity, offering broad market prospects. The team’s exceptional continuous innovation capability and execution strength have been fully recognized by the lead investor, making Baicare a scarce and valuable asset in the domestic market. We look forward to Baicare further enhancing its product R&D and manufacturing processes, accelerating its international expansion, and emerging as an industry leader in all-in-one nucleic acid testing devices following the completion of this financing round.

As a National High-Tech Enterprise, Zhongguancun High-Tech Enterprise, and Specialized, Refined, Differential, and Innovative (SRDI) SME, Beijing Baicare Biotechnology Co., Ltd. has received support from key deployment projects of the Chinese Academy of Sciences (CAS) and the National Science and Technology Major Project during the 13th Five-Year Plan period. The company has established close collaborative partnerships with Academician Zhong Nanshan’s team, the Guangzhou Institute of Respiratory Health, the Chinese Academy of Sciences, the Academy of Military Medical Sciences, and Peking Union Medical College Hospital. Holding multiple independent intellectual property rights, Baicare operates a 11,000-square-meter R&D and production center in Beijing and Tianjin, and has consecutively won awards such as the “Top 10 of the Zhongguancun International Frontier Technology Innovation Competition” and the “HICOOL Global Entrepreneurship Competition.”

Haoyue Capital was founded in January 2014, committed to serving as a bridge between China’s healthcare industry and capital markets. Its research and transaction coverage spans multiple sub-sectors, including biopharmaceuticals, innovative medical devices, IVD and precision medicine, healthcare services, and smart healthcare. The Haoyue Capital team comprises senior investment bankers with years of deep expertise in China’s healthcare sector. It closely monitors market dynamics and investment trends in healthcare, publishing weekly investment reports and thematic research studies to interpret new policies and emerging frontiers from the Haoyue perspective.